
    
      To determine the safety and efficacy of Cesamet™ in the symptomatic treatment of
      chemotherapy-induced neuropathic pain.

      This is a phase IV, multicenter, open label of Cesamet™ at 1 mg daily progressing to 2mg BID
      in subjects with chemotherapy-induced neuropathic pain. This study has two phases: A
      pretreatment phase and a treatment phase.
    
  